XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE Evidence

Request a Rep

XIENCE™ Stent Evidence

XIENCE™ Stent is the DES that delivers consistently outstanding short- and long-term patient outcomes.²

In fact XIENCE™ Stent consistently has the lowest rate of late and very late stent thrombosis (ST)—not only a year but a decade after the intervention—providing evidence that the XIENCE™ Stent's unparalleled patient outcomes last far beyond the intervention.¹

Long-Term Patient Data

XIENCE™ Stent’s Consistently Low Rates of Late and Very Late Stent Thrombosis¹

7-Year TLR Data

Long-term restenosis rates are also low, as shown by freedom from clinically driven target lesion revascularisation (CD-TLR) at 7 years.⁹

93% of patients were free from target lesion revascularization 7 years after the XIENCE Stent implant

Optimal Device Success

XIENCE™ Stent data shows consistent device success—and in all types of patients and lesions.

Improved Quality of Life with XIENCE™ Stent¹¹

XIENCE™ Stent has been shown to improve the quality of life of left main patients out to 3 years with 81% of patients reporting that they were angina free.

See the long-term results in complex patients treated with XIENCE™ Stent.

Improved QOL at 3 Years¹¹

70% of patients had no angina symptoms 3 years after XIENCE Stent implant

Explore Abbott's technologies for your needs.

Access personalised education and training

How can we help? Reach Abbott’s fast support here.

References

Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
Zanchin C. et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
Mehran R, et al. TCT Connect - XIENCE 28/90.
Von Birgele C, et al. J Am Coll Cardiol. 2012;59(15):1350-1361.
Van Geuns RJ, et al. TCT 2019, IDEAL-LM.
Chevalier B, et al. EuroIntervention. 2018;13(13):1561-1564.
Gao R, et al. TCT 2019, ABSORB China.
Kufner S, et al. Circulation. 2019:139(3):325-333.
Shiomi H, et al. JACC Cardiovasc Interv. 2019;12(7):637-647.
Saito S, et al. Eur Heart J. 2014;35:2021-2031. Saito S, et al. EuroIntervention. 2019;15(11):e1006-e1013. Natsuaki M, et al. J Am Coll Cardiol. 2013;62(3):181-190. Stone G, et al. Lancet. 2018:392:1530-40.
Note: 99% was the lowest device success rate.
Baron SJ, et al. J Am Coll Cardiol. 2017;70(25):3113-3122.

MAT-2413719 V1.0

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

XIENCE™ Stent Evidence

Long-Term Patient Data